- In a regulatory filing, Depomed (DEPO -0.3%) reports that, by mutual agreement, it has ended its legal fight with Horizon Pharma (HZNP -3%) stemming from the latter's unsolicited hostile offer and its alleged misuse of confidential information related to NUCYNTA (tapentadol). Both firms agreed to settle their respective claims against each other.
- Horizon also agreed to maintain the confidentiality of applicable information related to NUCYNTA that it received from Janssen Pharmaceuticals and not use said information. It also committed to not initiate another hostile bid for Depomed through January 1, 2020.